A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis

European Journal of Clinical Pharmacology

Volumn 67, Issue 8, 2011, Pages 759-766

  Huang, Xuan ^a   Lv, Bin ^a,b   Jin, Hai Feng ^a   Zhang, Shuo ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b NONE   (China)

Author keywords

Meta analysis; Therapeutic effects; Tumor necrosis factor blocker; Ulcerative colitis

Indexed keywords

ADALIMUMAB; INFLIXIMAB; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; COLON RESECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPTICEMIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 79960951518     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1079-3     Document Type: Review

References (32)

1. Lakatos PL (2006) Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 12:6102-6108
2. Kornbluth A, Sachar DB (2004) Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99:1371-1385 (Pubitemid 39062279)
3. Carter MJ, Lobo AJ, Travis SP (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (Suppl 5):V1-V16 (Pubitemid 39120096)
4. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709 (Pubitemid 23353163)
5. Rahimi R, Nikfar S, Abdollahi M (2007) Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 13:I13-I118
6. Lawson MM, Thomas AG, Akobeng AK (2006) Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3:CD005112
7. Ford AC, Sandborn WJ, Khan KJ et al (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644-659
8. Sands BE, Tremaine WJ, Sandborn WJ et al (2001) Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7:83-88
9. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52:998-1002 (Pubitemid 36765292)
10. Armuzzi A, De Pascalis B, Lupascu A et al (2004) Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8:231-233 (Pubitemid 39654526)
11. Ochsenkuhn T, Sackmann M, Goke B (2004) Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 16:1167-1171 (Pubitemid 39488789)
12. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-2476 (Pubitemid 41770166)
13. Jarnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805-1811 (Pubitemid 40824691)
14. Feagan BG, Reinisch W, Rutgeerts P et al (2007) The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 102:794-802 (Pubitemid 46496629)
15. Sandborn WJ, Rutgeerts P, Feagan BG et al (2009) Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137:1250-1260
16. Reinisch W, Sandborn WJ, Hommes DWet al (2010) Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 138(suppl 1):114-115
17. Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(Suppl 1):S3-S9
18. Mueller C (2002) Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunology 105:1-8
19. Raddatz D, Bockemuhl M, Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547-557 (Pubitemid 40592713)
20. Watanabe C, Miura S, Hokari R et al (2002) Spatial heterogeneity of TNF-alpha-induced T cell migration to colonic mucosa is mediated by MAdCAM-1 and VCAM-1. Am J Physiol Gastrointest Liver Physiol 283:G1379-G1387 (Pubitemid 35351126)
21. Irving PM, Macey MG, Feakins RM et al (2008) Platelet-leucocyte aggregates form in the mesenteric vasculature in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 20:283-289 (Pubitemid 351374231)
22. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549 (Pubitemid 34621118)
23. Targan SR, Feagan BG, Fedorak RN et al (2007) Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132:1672-1683 (Pubitemid 46695722)
24. Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357:228-238 (Pubitemid 47080387)
25. Regueiro M, Curtis J, Plevy S (2006) Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 40:476-481 (Pubitemid 44318131)
26. Probert CS, Hearing SD, Schreiber S et al (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52:998-1002 (Pubitemid 36765292)
27. Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451-459 (Pubitemid 38182302)
28. Rutter MD, Saunders BP, Wilkinson KH et al (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53:1813-1816
29. Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13:1024-1030
30. Leung Y, Hanauer SB (2009) Conventional treatment in inflammatory bowel disease - recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol 33(Suppl 3):S202-S208
31. Fan W, Maoqing W, Wangyang C et al (2011) Relationship between the polymorphism of tumor necrosis factor-α-308 G>A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet 19:432-437
32. Lu Z, Chen L, Li H et al (2008) Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion 78:44-51